Table 1.
Baseline and laboratory characteristics.
| Variable | All (n = 60) | Anterograde (n = 31) | Retrograde (n = 29) | P value |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (IQR), years | 64 (52–69) | 64 (60–70) | 60 (41–68) | 0.20 |
| Men, n (%) | 51 (85.0%) | 24 (77.4%) | 27 (93.1%) | 0.15 |
| Medical history | ||||
| Atrial fibrillation, n (%) | 8 (13.3%) | 7 (22.6%) | 1 (3.4%) | 0.05 |
| Hypertension, n (%) | 30 (50.0%) | 19 (61.3%) | 11 (37.9%) | 0.07 |
| Diabetes mellitus, n (%) | 11 (18.3%) | 8 (25.8%) | 3 (10.3%) | 0.12 |
| Hyperlipidemia, n (%) | 5 (8.3%) | 4 (12.9%) | 1 (3.4%) | 0.36 |
| Current smoker, n (%) | 25 (41.7%) | 11 (35.5%) | 14 (48.3%) | 0.32 |
| Artery occlusion aetiology | 0.02 | |||
| Atherosclerosis, n (%) | 40 (66.7%) | 21 (67.7%) | 19 (65.5%) | |
| Cardioembolism, n (%) | 8 (13.3%) | 7 (22.6%) | 1 (3.4%) | |
| Dissection, n (%) | 11 (18.3%) | 2 (6.5%) | 9 (31.0%) | |
| Undetermined aetiology, n (%) | 1 (1.7%) | 1 (3.2%) | 0 | |
| Laboratory measures | ||||
| TG, median (IQR), mmol/L | 1.03 (0.71–1.89) | 1.19 (0.76–1.88) | 0.95 (0.64–2.10) | 0.38 |
| TC, median (IQR), mmol/L | 4.16 (3.59–5.09) | 4.16 (3.71–5.04) | 4.07 (3.45–5.19) | 0.88 |
| HDL, mean (IQR), mmol/L | 1.21 (1.01–1.52) | 1.28 (0.96–1.54) | 1.15 (1.01–1.40) | 0.44 |
| LDL, mean (SD), mmol/L | 2.56 (0.86) | 2.54 (0.74) | 2.57 (0.98) | 0.91 |
| Glu, median (IQR), mmol/L | 6.90 (5.46–8.80) | 7.53 (5.73–9.30) | 6.48 (5.45–7.40) | 0.19 |
| Clinical characteristics | ||||
| SBP, mean (SD), mmHg | 142 (21) | 142 (20) | 142 (23) | 0.99 |
| Baseline ASPECTS, median (IQR) | 9 (8–10) | 9 (8–10) | 9 (8–10) | 0.72 |
| Baseline NIHSS score, mean (SD) | 17 (6) | 17 (8) | 16 (3) | 0.92 |
SD: standard deviation; IQR: interquartile range; TG: triglyceride; TC: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; Glu: glucose; SBP: systolic blood pressure; ASPECTS: Alberta Stroke Program early CT score; NIHSS: National Institutes of Health stroke scale.